Home > Gastroenterology > DDW 2022 > Other Highlighted Research > Octreotide therapy beats standard of care in GIADs

Octreotide therapy beats standard of care in GIADs

Presented By
Ms Lia Goltstein, Radboud University Medical Center, the Netherlands
Presented by
Lia Goltstein Radboud University Medical Center
Conference
DDW 2022
Doi
https://doi.org/10.55788/5db1456f
The somatostatin analogue octreotide was investigated for the treatment of gastrointestinal angiodysplasias (GIADS) with anaemia. The results showed that therapy with octreotide led to a marked reduction of transfusions and the necessity of rescue treatment. “GIADs are vascular malformations that frequently cause patients to suffer from symptomatic disease, ranging from mild anaemia to severe red blood cell transfusion dependency,” explained Ms Lia Goltstein (Radboud University Medical Center, the Netherlands), who presented a trial that compared octreotide in GIAD treatment with standard of care (SoC) [1]. The study recruited 62 Dutch patients between 2015 and 2021. A prerequisite for inclusion was a need for ≥4 transfusions of either red blood cells with or without 500 mg of iron intravenous in the year before the study. The 2 study groups received either 40 mg of intramuscular octreotide every 28 days or SoC. The primary endpoint was defined as ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on